Oropharyngeal Cancer, HPV and TransOral Robotic Surgery (TORS)

Published Nov 7, 2024
Updated Jun 14, 2026
H&N Cancer
Epidemiology of HPV-Related Oropharyngeal Cancer and Current Trends
Oropharyngeal cancer, specifically in the tonsils and the base of the tongue, has seen a rise in incidence in recent years, particularly in developed countries. Human papillomavirus (HPV), especially HPV type 16, has been identified as a significant contributing factor. Unlike traditional risk factors such as smoking and alcohol, HPV-related oropharyngeal cancers are increasingly affecting younger, non-smoking individuals, particularly males. HPV-positive oropharyngeal cancers often have a better prognosis and response to treatment compared to HPV-negative cases.
Current trends indicate that HPV-related oropharyngeal cancer will continue to rise, driven by transmission dynamics of HPV through oral-genital contact, with vaccination efforts aimed at curbing this trend over the long term.
Contributions of Robotic Surgery
Transoral Robotic Surgery (TORS), has become an important tool in treating oropharyngeal cancer, providing several advantages over traditional surgery. TORS allows surgeons to access the oropharynx through the mouth, avoiding large external incisions and minimizing damage to surrounding tissues. This minimally invasive approach reduces recovery time, leads to fewer complications, and often preserves swallowing and speech functions better than conventional methods. Robotic surgery has proven to be particularly beneficial for HPV-positive tumors, which respond well to local treatment and may require less aggressive interventions than HPV-negative cases. Overall, robotic surgery is advancing the field by improving both survival rates and quality of life for oropharyngeal cancer patients (see the latest ASCO guideline)
Resorces:
Related posts:
- AJCC Version 9 Cancer Staging System for HPV-Associated Oropharyngeal Cancer Jun 15, 2026
- Oropharyngeal Cancer. Update 2026. Jun 12, 2026
- Oropharyngeal squamous cell carcinoma. Three questions. One decision. Mar 4, 2026
- HPV-Associated Oropharyngeal Cancer in Spain: Are We Already Above 50%?. Feb 17, 2026
- Human PapillomaVirus – Related Oropharyngeal Cancer. Dec 9, 2025
- Human Papillomavirus and Cancer of the Oropharynx (FAQ). July 5, 2025
- Transoral Robotic Surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO Guideline. Feb 15, 2025
- Transoral surgery may offer better survival outcomes for elderly patients with HPV-related OPSCC compared to primary radiotherapy Feb 9, 2025
- The case against lingual mucosectomy Nov 11, 2024
- The ORATOR randomized trial Nov 4, 2024
- PuraShield Nov 3, 2024
- Update in Oropharyngeal Cancer: Malaga 2024 Oct 28, 2024
- Cáncer de orofaringe y cirugía robótica. Carta abierta. Jul 7, 2024
- On overtreatment and de-escalation Apr 14, 2024
- Head and Neck Cancer Committee (Oropharynx). Case presentation. Jun 25, 2023
- Information for patients Aug 26, 2021





